[1] |
中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组. 外用中成药治疗湿疹皮炎的专家共识(2014)[J]. 中华皮肤科杂志, 2014, 47(6): 440⁃441. DOI: 10.3760/cma.j.issn.0412⁃4030.2014.06.023.
|
|
Environmental and Occupational Skin Disease Group, Committee on Dermatology and Venereology, China Society of Integrated Traditional Chinese and Western Medicine. Topical treatment of eczema and dermatitis with traditional Chinese medicines: an expert consensus statement[J]. Chin J Dermatol, 2014, 47(6): 440⁃441. DOI: 10.3760/cma.j.issn.0412⁃4030.2014.06.023.
|
[2] |
李园园, 李邻峰. 青鹏软膏对小鼠特应性皮炎模型的影响及机制研究[J]. 中华皮肤科杂志, 2013, 46(1): 24⁃27. DOI: 10.3760/cma.j.issn.0412⁃4030.2013.01.009.
|
|
Li YY, Li LF. Effect of Qingpeng ointment on experimental atopic dermatitis in mice and its possible mechanisms[J]. Chin J Dermatol, 2013, 46(1): 24⁃27. DOI: 10.3760/cma.j.issn.0412⁃4030. 2013.01.009.
|
[3] |
李园园, 李邻峰. 青鹏软膏对小鼠实验性刺激性接触性皮炎的抑制作用及可能机制研究[J]. 中华皮肤科杂志, 2012, 45(9): 650⁃654. DOI: 10.3760/cma.j.issn.0412⁃4030.2012.09.013.
|
|
Li YY, Li LF. Inhibitory effect of Qingpeng ointment on experimental irritant contact dermatitis in mice and its possible mechanisms[J]. Chin J Dermatol, 2012, 45(9): 650⁃654. DOI: 10.3760/cma.j.issn.0412⁃4030.2012.09.013.
|
[4] |
路雪艳, 李云珠, 门月华, 等. 特应性皮炎样小鼠模型皮肤屏障功能受损的分子机制研究[J]. 中国麻风皮肤病杂志, 2013, 29(3): 164⁃167. DOI: 10.3969/j.issn.1009⁃1157.2013.03.006.
|
|
Lu XY, Li YZ, Men YH, et al. Study on molecular mechanisms of impaired skin barrier function in an atopic dermatitis⁃like animal model[J]. Chin J Lepr Skin Dis, 2013, 29(3): 164⁃167. DOI: 10.3969/j.issn.1009⁃1157.2013.03.006.
|
[5] |
Li YZ, Lu XY, Jiang W, et al. Anti⁃inflammatory effect of qingpeng ointment in atopic dermatitis⁃like murine model[J].Evid Based Complement Alternat Med, 2013, 2013: 907016. DOI: 10.1155/2013/907016.
|
[6] |
Kim BE, Leung DY. Epidermal barrier in atopic dermatitis[J]. Allergy Asthma Immunol, Res, 2012, 4(1): 12⁃16. DOI: 10.4168/aair.2012.4.1.12.
|
[7] |
Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier[J]. Exp Dermatol, 2008, 17(12): 1063⁃1072.
|
[8] |
Weidinger S, Baurecht H, Wagenpfeil S, et al. Analysis of the individual and aggregate genetic contributions of previously identified serine peptidase inhibitor Kazal type 5 (SPINK5), kallikrein⁃related peptidase 7 (KLK7), and filaggrin (FLG) polymorphisms to eczema risk[J]. J Allergy Clin Immunol, 2008, 122(3): 560⁃568. DOI: 10.1016/j.jaci.2008.05.050.
|
[9] |
Cork MJ, Danby SG, Vasilopoulos Y, et al. Epidermal barrier dysfunction in atopic dermatitis[J]. J Invest Dermatol, 2009, 129(8): 1892⁃1908. DOI: 10.1038/jid.2009.133.
|
[10] |
Kim BE, Leung DY, Boguniewicz M, et al. Loricrin and involucrin is down⁃regulated by Th2 cytokines through STAT⁃6[J]. Clin Immunol, 2008, 126(3): 332⁃337. DOI: 10.1016/j.clim.2007.11.006.
|
[11] |
Komatsu N, Saijoh K, Kuk C, et al. Human tissue kallikrein in the stratum corneum and serum of atopic dermatitis patients[J]. Exp Dermatol, 2007, 16(6): 513⁃519. DOI: 10.1111/j.1600⁃0625.2007.00562.x.
|
[12] |
Sevilla LM, Nachat R, Groot KR, et al. Mice deficient in involucrin, envoplakin, and periplakin have a defective epidermal barrier[J]. J Cell Biol, 2007, 179 (7): 1599⁃1612. DOI: 10.1083/jcb.200706187.
|
[13] |
Hansson L, Bäckman A, Ny A, et al. Epidermal over of stratum corneum chymotryptic enzyme in mice: a model for chronic itchy dermatitis[J]. J Invest Dermatol, 2002, 118(3): 444⁃449. DOI: 10.1046/j.0022⁃202x.2001.01684.x.
|
[14] |
Buraczewska I, Berne B, Lindberg M, et al. Long⁃term treatment with moisturizers affects the mRNA levels of genes involved in keratinocyte differentiation and desquamation[J]. Arch Dermatol Res, 2009, 301(2): 175⁃181. DOI: 10.1007/s00403⁃008-0906⁃6.
|